Thursday, March 30, 2006 11:13:50 AM
AP, Thursday March 30, 6:56 am ET
Amylin Pharmaceuticals Raises Proceeds of $441.4 Million in Public Stock Offering
http://finance.yahoo.com/q?s=AMLN
SAN DIEGO (AP) -- Biopharmaceutical company Amylin Pharmaceuticals Inc. said Thursday a public offering of 10 million shares at $46.50 each raised net proceeds of about $441.4 million.
The company has granted underwriters an overallotment option to purchase up to an additional 1.5 million shares.
Amylin, which develops therapies to treat diabetes and associates disorders, said in a regulatory filing it plans to use proceeds to commercialize approved products, fund the development of drug candidates, increase research and development and for other general corporate purposes.
Morgan Stanley & Co. is the sole bookrunning and co-lead manager for the offering, Goldman Sachs & Co. is co-lead manager, and co-managers are Bear Stearns & Co. and Lehman Brothers Inc.
Amylin Pharmaceuticals has about 111.5 million shares outstanding. Shares of the company closed Wednesday at $46.86 on the Nasdaq.
http://biz.yahoo.com/ap/060330/amylin_pharma_stock_offer.html?.v=1
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM